Cellular reprogramming by protein degradation: The next frontier in cancer immunotherapy.

Erik Ehinger, Anjana Rao
Author Information
  1. Erik Ehinger: Division of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA, USA; Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, CA, USA; Department of Pharmacology, University of California, San Diego, La Jolla, CA, USA. Electronic address: eehinger@lji.org.
  2. Anjana Rao: Division of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA, USA; Department of Pharmacology, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA. Electronic address: arao@lji.org.

Abstract

In this issue of Cell Chemical Biology, Lane et al. introduce a transgene-based system to express fusion proteins that recruit transcription factors to E3 ligases. This approach expands the target repertoire for engineered cell therapies as exemplified by the targeting of SMAD proteins to overcome a TGF��-mediated suppressive mechanism that weakens anti-tumor responses.

Grants

  1. R01 AI040127/NIAID NIH HHS
  2. U01 DE028227/NIDCR NIH HHS

MeSH Term

Humans
Proteolysis
Signal Transduction
Ubiquitin-Protein Ligases
Neoplasms
Immunotherapy
Cellular Reprogramming

Chemicals

Ubiquitin-Protein Ligases

Word Cloud

Created with Highcharts 10.0.0proteinsissueCellChemicalBiologyLaneet alintroducetransgene-basedsystemexpressfusionrecruittranscriptionfactorsE3ligasesapproachexpandstargetrepertoireengineeredcelltherapiesexemplifiedtargetingSMADovercomeTGF��-mediatedsuppressivemechanismweakensanti-tumorresponsesCellularreprogrammingproteindegradation:nextfrontiercancerimmunotherapy

Similar Articles

Cited By